Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
Recruiting
Bristol-Myers Squibb
Early Phase 1
2023-01-19
The purpose of this pilot study is to determine the safety and feasibility of giving a single
dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from
melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after
receiving the study drug.
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
Recruiting
H. Lee Moffitt Cancer Center and Research Institute
Early Phase 1
2023-01-19
The purpose of this pilot study is to determine the safety and feasibility of giving a single
dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from
melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after
receiving the study drug.
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Recruiting
Bristol-Myers Squibb
Phase 2
2023-11-08
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous
(SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience
data by route of administration. This study will also generate safety data which will further
characterize the safety profile of patients switching the route of administration from
intravenous (IV) to SC.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
